CORT vs. CLS.TO
CORT (Corcept Therapeutics Incorporated) and CLS.TO (Celestica Inc.) are both stocks. CORT operates in Biotechnology (Healthcare), while CLS.TO operates in Electronic Components (Technology). Over the past 10 years, CORT returned 29.33%/yr vs 43.13%/yr for CLS.TO. At a 0.15 correlation, their price movements are largely independent.
Performance
CORT vs. CLS.TO - Performance Comparison
Loading charts...
Different Trading Currencies
CORT is traded in USD, while CLS.TO is traded in CAD. To make them comparable, the CLS.TO values have been converted to USD using the latest available exchange rates.
Returns By Period
In the year-to-date period, CORT achieves a 110.72% return, which is significantly higher than CLS.TO's 30.20% return. Over the past 10 years, CORT has underperformed CLS.TO with an annualized return of 29.33%, while CLS.TO has yielded a comparatively higher 43.13% annualized return.
CORT
- 1D
- 0.98%
- 1M
- 40.26%
- YTD
- 110.72%
- 6M
- -11.63%
- 1Y
- 5.36%
- 3Y*
- 46.50%
- 5Y*
- 27.35%
- 10Y*
- 29.33%
CLS.TO
- 1D
- 3.51%
- 1M
- 2.58%
- YTD
- 30.20%
- 6M
- 13.02%
- 1Y
- 218.72%
- 3Y*
- 209.37%
- 5Y*
- 114.69%
- 10Y*
- 43.13%
CORT vs. CLS.TO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
CORT Corcept Therapeutics Incorporated | 110.72% | -30.94% | 55.14% | 59.92% | 2.58% | -24.31% | 116.20% | -9.43% | -26.02% | 148.76% |
CLS.TO Celestica Inc. | 30.20% | 220.69% | 215.14% | 160.52% | 1.78% | 37.36% | -2.32% | -6.08% | -16.29% | -11.14% |
Correlation
The correlation between CORT and CLS.TO is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.21 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.20 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.21 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.17 |
Correlation (All Time) Calculated using the full available price history since Jul 6, 2006 | 0.15 |
Fundamentals
CORT:
$7.66B
CLS.TO:
CA$62.28B
CORT:
$0.41
CLS.TO:
CA$8.28
CORT:
178.81
CLS.TO:
64.97
CORT:
89.07
CLS.TO:
0.87
CORT:
11.07
CLS.TO:
4.52
CORT:
12.00
CLS.TO:
29.68
CORT:
$769.10M
CLS.TO:
CA$13.81B
CORT:
$755.64M
CLS.TO:
CA$1.60B
CORT:
$3.66M
CLS.TO:
CA$1.36B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CORT vs. CLS.TO — Risk / Return Rank
CORT
CLS.TO
CORT vs. CLS.TO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Corcept Therapeutics Incorporated (CORT) and Celestica Inc. (CLS.TO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CORT | CLS.TO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -3.00 | ||
| Sortino ratioReturn per unit of downside risk | -2.29 | ||
| Omega ratioGain probability vs. loss probability | 1.14 | 1.40 | -0.26 |
| Calmar ratioReturn relative to maximum drawdown | 0.08 | 7.45 | -7.37 |
| Martin ratioReturn relative to average drawdown | 0.15 | 18.87 | -18.72 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| CORT | CLS.TO | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.07 | 3.07 | -3.00 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.37 | 2.04 | -1.67 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.44 | 0.88 | -0.44 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.11 | 0.43 | -0.32 |
Drawdowns
CORT vs. CLS.TO - Drawdown Comparison
The maximum CORT drawdown since its inception was -94.28%, which is greater than CLS.TO's maximum drawdown of -80.63%. Use the drawdown chart below to compare losses from any high point for CORT and CLS.TO.
Loading charts...
Drawdown Indicators
| CORT | CLS.TO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.28% | -80.63% | -13.65% |
Max Drawdown (1Y)Largest decline over 1 year | -64.40% | -29.56% | -34.84% |
Max Drawdown (3Y)Largest decline over 3 years | -71.85% | -53.42% | -18.43% |
Max Drawdown (5Y)Largest decline over 5 years | -71.85% | -53.42% | -18.43% |
Max Drawdown (10Y)Largest decline over 10 years | -71.85% | -80.63% | +8.78% |
Current DrawdownCurrent decline from peak | -35.80% | -18.17% | -17.63% |
Average DrawdownAverage peak-to-trough decline | -53.44% | -26.18% | -27.26% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 35.34% | 11.65% | +23.69% |
Volatility
CORT vs. CLS.TO - Volatility Comparison
The current volatility for Corcept Therapeutics Incorporated (CORT) is 16.41%, while Celestica Inc. (CLS.TO) has a volatility of 27.08%. This indicates that CORT experiences smaller price fluctuations and is considered to be less risky than CLS.TO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CORT | CLS.TO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 16.41% | 27.08% | -10.67% |
Volatility (6M)Calculated over the trailing 6-month period | 85.07% | 55.16% | +29.91% |
Volatility (1Y)Calculated over the trailing 1-year period | 76.73% | 71.89% | +4.84% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 74.52% | 56.76% | +17.76% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 67.22% | 49.36% | +17.86% |
Dividends
CORT vs. CLS.TO - Dividend Comparison
Neither CORT nor CLS.TO has paid dividends to shareholders.
Financials
CORT vs. CLS.TO - Financials Comparison
This section allows you to compare key financial metrics between Corcept Therapeutics Incorporated and Celestica Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CORT vs. CLS.TO - Profitability Comparison
CORT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a gross profit of 162.02M and revenue of 164.90M. Therefore, the gross margin over that period was 98.3%.
CLS.TO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported a gross profit of 437.20M and revenue of 4.05B. Therefore, the gross margin over that period was 10.8%.
CORT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported an operating income of -49.60M and revenue of 164.90M, resulting in an operating margin of -30.1%.
CLS.TO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported an operating income of 267.70M and revenue of 4.05B, resulting in an operating margin of 6.6%.
CORT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a net income of -31.20M and revenue of 164.90M, resulting in a net margin of -18.9%.
CLS.TO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported a net income of 212.30M and revenue of 4.05B, resulting in a net margin of 5.3%.
Frequently Asked Questions
CORT and CLS.TO have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for CORT and CLS.TO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer